Editas Medicine Q1 net loss $62M; cash $376.8M; reni-cel adult cohort enrollment complete

Editas Medicine, Inc.

2024-Q1 EPS reported -$0.76 revenue$1,135,000

Q1 2024 net loss $62.0M ($0.76/share) vs $49.0M ($0.71) in Q1 2023; collaboration revenue fell to $1.1M from $9.9M.
Cash, equivalents, and marketable securities $376.8M at March 31, 2024; runway into 2026.
R&D expenses rose to $48.8M from $37.8M driven by reni-cel clinical and manufacturing costs.
Completed adult cohort enrollment in RUBY trial for sickle cell disease; enrolled multiple adolescent patients.
Extended Bristol Myers Squibb collaboration by two years; CAFC oral arguments held for CRISPR patent interference.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Editas Medicine, Inc. reported first quarter 2024 results: net income net loss of $62.0 million, EPS -$0.76.

Period: first quarter 2024
Net income: net loss of $62.0 million
EPS: -$0.76
Result: reported results

Exact text from the filing

For the three months ended March 31, 2024, net loss attributable to common stockholders was $62.0 million, or $0.76 per share, compared to net loss of $49.0 million, or $0.71 per share, for the same period in 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001650664-24-000034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.